All In Biotech

Drug Trial Radar · NCT07649265

A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body

A Phase 1 Open-Label, Multicenter Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HBM7020 in Healthy Adult Participants and Adults With Seropositive Autoimmune Disease

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

63

Planned (sponsor's estimate)

Start

Sep 24, 2026

Primary completion

Nov 20, 2028

Study completion Nov 20, 2028

Sponsor

Sponsor type
Industry
First posted
Jun 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This first-in-human study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of HBM7020. The study will enroll healthy participants at low doses, followed by participants with moderate to severe autoimmune diseases with predominant B-cell involvement. Eligible participants include patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's disease (SjD), and rheumatoid arthritis (RA).

Conditions

  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Systemic Sclerosis
  • Sjögren's Disease

Interventions

  • HBM7020Drug

    Liquid formulation, administered through intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Discontinuations Due to Adverse Events Through Week 48Time frame: Up to Week 48
  2. Number of Participants With Signs Characteristic of Cytokine Release Syndrome (CRS), Immune Related Reaction (IRR), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), Including Immunosuppression-Related InfectionTime frame: Up to Week 24
  3. Number of Participants With Dose limiting AE Evaluation During Dose EscalationTime frame: Up to Day 15
  4. Number of Participants With Clinically Significant Changes in Vital SignsTime frame: Up to Week 24
  5. Number of Participants With Clinically Significant Changes in Physical Examination FindingsTime frame: Up to Week 24
  6. Change From Baseline in Serum High Sensitivity C-Reactive Protein (hsCRP)Time frame: Up to Week 20
  7. Change From Baseline in Serum Erythrocyte Sedimentation Rate (ESR)Time frame: Up to Week 20
  8. Change From Baseline in Serum FerritinTime frame: Up to Week 20
  9. Change From Baseline in Serum Immunoglobulin G (IgG)Time frame: Up to Week 20

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Q-Pharm Pty Ltd

    Brisbane, Queensland, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.